We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Accenture, Wells Fargo and Uber
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 19, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Incorporated (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) , Accenture plc (ACN - Free Report) , Wells Fargo & Company (WFC - Free Report) and Uber Technologies, Inc. (UBER - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for UnitedHealth, Pfizer and Accenture
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Pfizer, and Accenture. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of UnitedHealth have outperformed the Zacks Medical Insurance industry over the past year (+33.4% vs. +29.1%). The Zacks analyst believes that the company's top line is bolstered by numerous acquisitions, new deals, renewed agreements and expansion of service offerings.
Its solid health services segment provides significant diversification benefits. Further, the company remains well poised to gain from its government business. A sturdy balance sheet and consistent cash flow generation are other positives, which led to a solid capital position.
This enables the company to engage in share buybacks and dividend payments. A strong 2021 view buoys investor optimism on the stock. However, the company is witnessing a slowdown in international and commercial business.
Pfizer shares have gained +0.8% over the last six months against the Zacks Large-Cap Pharmaceuticals industry's gain of +6.5%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Further, Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Furthermore, its COVID-19 vaccine candidate is now approved for emergency use in several countries.
However, currency headwinds and pricing pressure are key top-line headwinds. Meanwhile, its Upjohn unit was a cash rich business and its divestiture will reduce the company's cash flow.
Shares of Accenture have gained +12.7% in the past three months against the Zacks Consulting industry's gain of +12.3%. The Zacks analyst believes that the company has been steadily gaining traction in its outsourcing and consulting businesses.
Moreover, it has been strategically enhancing its cloud and digital marketing suite through acquisitions and partnerships. Accenture's strong operating cash flow has helped it reward its shareholders in the form of dividends as well as pursue opportunities in areas that show true potential.
However, pricing pressure due to significant competition from strong companies like Genpact, Cognizant and Infosys, remains a concern. Global presence exposes it to foreign currency exchange rate fluctuations. Buyout-related integration risks continue to remain a concern.
Other noteworthy reports we are featuring today include Wells Fargo and Uber Technologies.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It's bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is "Will you get into the right stocks early when their growth potential is greatest?"
Zacks has released a Special Report to help you do just that, and today it's free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Accenture, Wells Fargo and Uber
For Immediate Release
Chicago, IL – April 19, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Incorporated (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) , Accenture plc (ACN - Free Report) , Wells Fargo & Company (WFC - Free Report) and Uber Technologies, Inc. (UBER - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for UnitedHealth, Pfizer and Accenture
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Pfizer, and Accenture. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of UnitedHealth have outperformed the Zacks Medical Insurance industry over the past year (+33.4% vs. +29.1%). The Zacks analyst believes that the company's top line is bolstered by numerous acquisitions, new deals, renewed agreements and expansion of service offerings.
Its solid health services segment provides significant diversification benefits. Further, the company remains well poised to gain from its government business. A sturdy balance sheet and consistent cash flow generation are other positives, which led to a solid capital position.
This enables the company to engage in share buybacks and dividend payments. A strong 2021 view buoys investor optimism on the stock. However, the company is witnessing a slowdown in international and commercial business.
(You can read the full research report on UnitedHealth here >>>)
Pfizer shares have gained +0.8% over the last six months against the Zacks Large-Cap Pharmaceuticals industry's gain of +6.5%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Further, Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Furthermore, its COVID-19 vaccine candidate is now approved for emergency use in several countries.
However, currency headwinds and pricing pressure are key top-line headwinds. Meanwhile, its Upjohn unit was a cash rich business and its divestiture will reduce the company's cash flow.
(You can read the full research report on Pfizer here >>>)
Shares of Accenture have gained +12.7% in the past three months against the Zacks Consulting industry's gain of +12.3%. The Zacks analyst believes that the company has been steadily gaining traction in its outsourcing and consulting businesses.
Moreover, it has been strategically enhancing its cloud and digital marketing suite through acquisitions and partnerships. Accenture's strong operating cash flow has helped it reward its shareholders in the form of dividends as well as pursue opportunities in areas that show true potential.
However, pricing pressure due to significant competition from strong companies like Genpact, Cognizant and Infosys, remains a concern. Global presence exposes it to foreign currency exchange rate fluctuations. Buyout-related integration risks continue to remain a concern.
(You can read the full research report on Accenture here >>>)
Other noteworthy reports we are featuring today include Wells Fargo and Uber Technologies.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It's bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is "Will you get into the right stocks early when their growth potential is greatest?"
Zacks has released a Special Report to help you do just that, and today it's free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.